|
1
|
Jolly MK, Somarelli JA, Sheth M, Biddle A,
Tripathi SC, Armstrong AJ, Hanash SM, Bapat SA, Rangarajan A and
Levine H: Hybrid Epithelial/mesenchymal phenotypes promote
metastasis and therapy resistance across carcinomas. Pharmacol
Ther. 194:161–184. 2019. View Article : Google Scholar
|
|
2
|
Phan TG and Croucher PI: The dormant
cancer cell life cycle. Nat Rev Cancer. 20:398–411. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jenkins RW, Barbie DA and Flaherty KT:
Mechanisms of resistance to immune checkpoint inhibitors. Br J
Cancer. 118:9–16. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lopez JS and Banerji U: Combine and
conquer: Challenges for targeted therapy combinations in early
phase trials. Nat Rev Clin Oncol. 14:57–66. 2017. View Article : Google Scholar
|
|
5
|
Wilczyński JR, Wilczyński M and Paradowska
E: Cancer stem cells in ovarian cancer-a source of tumor success
and a challenging target for novel therapies. Int J Mol Sci.
23:24962022. View Article : Google Scholar
|
|
6
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Assaraf YG, Brozovic A, Gonçalves AC,
Jurkovicova D, Linē A, Machuqueiro M, Saponara S, Sarmento-Ribeiro
AB, Xavier CPR and Vasconcelos MH: The multi-factorial nature of
clinical multidrug resistance in cancer. Drug Resist Updat.
46:1006452019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schoenfeld AJ and Hellmann MD: Acquired
resistance to immune checkpoint inhibitors. Cancer Cell.
37:443–455. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aleksakhina SN, Kashyap A and Imyanitov
EN: Mechanisms of acquired tumor drug resistance. Biochim Biophys
Acta Rev Cancer. 1872:1883102019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xie Y, Feng SL, He F, Yan PY, Yao XJ, Fan
XX, Leung EL and Zhou H: Down-regulating Nrf2 by tangeretin
reverses multiple drug resistance to both chemotherapy and EGFR
tyrosine kinase inhibitors in lung cancer. Pharmacol Res.
186:1065142022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Makena MR, Ranjan A, Thirumala V and Reddy
AP: Cancer stem cells: Road to therapeutic resistance and
strategies to overcome resistance. Biochim Biophys Acta Mol Basis
Dis. 1866:1653392020. View Article : Google Scholar
|
|
12
|
Erin N, Grahovac J, Brozovic A and Efferth
T: Tumor micro-environment and epithelial mesenchymal transition as
targets to overcome tumor multidrug resistance. Drug Resist Updat.
53:1007152020. View Article : Google Scholar
|
|
13
|
Gourley C, Balmaña J, Ledermann JA, Serra
V, Dent R, Loibl S, Pujade-Lauraine E and Boulton SJ: Moving from
poly (ADP-Ribose) polymerase inhibition to targeting DNA repair and
DNA damage response in cancer therapy. J Clin Oncol. 37:2257–2269.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sundar R, Huang KK, Kumar V, Ramnarayanan
K, Demircioglu D, Her Z, Ong X, Bin Adam Isa ZF, Xing M, Tan AL, et
al: Epigenetic promoter alterations in GI tumour immune-editing and
resistance to immune checkpoint inhibition. Gut. 71:1277–1288.
2022. View Article : Google Scholar
|
|
15
|
Carneiro BA and El-Deiry WS: Targeting
apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kumar A and Jaitak V: Natural products as
multidrug resistance modulators in cancer. Eur J Med Chem.
176:268–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lai JI, Tseng YJ, Chen MH, Huang CF and
Chang PM: Clinical perspective of FDA approved drugs with
P-Glycoprotein inhibition activities for potential cancer
therapeutics. Front Oncol. 10:5619362020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Robey RW, Pluchino KM, Hall MD, Fojo AT,
Bates SE and Gottesman MM: Revisiting the role of ABC transporters
in multidrug-resistant cancer. Nat Rev Cancer. 18:452–464. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen Y, Zhang J, Zhang M, Song Y, Zhang Y,
Fan S, Ren S, Fu L, Zhang N, Hui H, et al: Baicalein resensitizes
tamoxifen-resistant breast cancer cells by reducing aerobic
glycolysis and reversing mitochondrial dysfunction via inhibition
of hypoxia-inducible factor-1α. Clin Transl Med. 11:e5772021.
View Article : Google Scholar
|
|
20
|
Zhai K, Mazurakova A, Koklesova L, Kubatka
P and Büsselberg D: Flavonoids synergistically enhance the
anti-glioblastoma effects of chemotherapeutic drugs. Biomolecules.
11:18412021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
He XL, Xu XH, Shi JJ, Huang M, Wang Y,
Chen X and Lu JJ: Anticancer effects of ginsenoside Rh2: A
systematic review. Curr Mol Pharmacol. 15:179–189. 2022.
|
|
22
|
Wang Y, Xu J, Wang Y, Xiang L and He X:
S-20, a steroidal saponin from the berries of black nightshade,
exerts anti-multidrug resistance activity in K562/ADR cells through
autophagic cell death and ERK activation. Food Funct. 13:2200–2215.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Tilaoui M, Ait Mouse H and Zyad A: Update
and new insights on future cancer drug candidates from plant-based
alkaloids. Front Pharmacol. 12:7196942021. View Article : Google Scholar :
|
|
24
|
Majidinia M, Mirza-Aghazadeh-Attari M,
Rahimi M, Mihanfar A, Karimian A, Safa A and Yousefi B: Overcoming
multidrug resistance in cancer: Recent progress in nanotechnology
and new horizons. IUBMB Life. 72:855–871. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo X, He D, Zhang E, Chen J, Chen Q, Li
Y, Yang L, Yang Y, Zhao Y, Wang G, et al: HMGB1 knockdown increases
MM cell vulnerability by regulating autophagy and DNA damage
repair. J Exp Clin Cancer Res. 37:2052018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Borde C, Dillard C, L'Honoré A, Quignon F,
Hamon M, Marchand CH, Faccion RS, Costa MGS, Pramil E, Larsen AK,
et al: The C-terminal acidic tail modulates the anti-cancer
properties of HMGB1. Int J Mol Sci. 23:78652022. View Article : Google Scholar
|
|
27
|
Gaikwad S, Puangmalai N, Bittar A,
Montalbano M, Garcia S, McAllen S, Bhatt N, Sonawane M, Sengupta U
and Kayed R: Tau oligomer induced HMGB1 release contributes to
cellular senescence and neuropathology linked to Alzheimer's
disease and frontotemporal dementia. Cell Rep. 36:1094192021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Stros M: HMGB proteins: Interactions with
DNA and chromatin. Biochim Biophys Acta. 1799:101–113. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wen B, Wei YT and Zhao K: The role of high
mobility group protein B3 (HMGB3) in tumor proliferation and drug
resistance. Mol Cell Biochem. 476:1729–1739. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Voong CK, Goodrich JA and Kugel JF:
Interactions of HMGB Proteins with the Genome and the Impact on
Disease. Biomolecules. 11:14512021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Catena R, Escoffier E, Caron C, Khochbin
S, Martianov I and Davidson I: HMGB4, a novel member of the HMGB
family, is preferentially expressed in the mouse testis and
localizes to the basal pole of elongating spermatids. Biol Reprod.
80:358–366. 2009. View Article : Google Scholar
|
|
32
|
Niu L, Yang W, Duan L, Wang X, Li Y, Xu C,
Liu C, Zhang Y, Zhou W, Liu J, et al: Biological functions and
theranostic potential of HMGB family members in human cancers. Ther
Adv Med Oncol. 12:17588359209708502020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Taniguchi N, Kawakami Y, Maruyama I and
Lotz M: HMGB proteins and arthritis. Hum Cell. 31:1–9. 2018.
View Article : Google Scholar
|
|
34
|
Bianchi ME, Crippa MP, Manfredi AA,
Mezzapelle R, Rovere Querini P and Venereau E: High-mobility group
box 1 protein orchestrates responses to tissue damage via
inflammation, innate and adaptive immunity, and tissue repair.
Immunol Rev. 280:74–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cheng KJ, Alshawsh MA, Mejia Mohamed EH,
Thavagnanam S, Sinniah A and Ibrahim ZA: HMGB1: An overview of its
versatile roles in the pathogenesis of colorectal cancer. Cell
Oncol (Dordr). 43:177–193. 2020. View Article : Google Scholar
|
|
36
|
Liu L, Liu S, Luo H, Chen C, Zhang X, He L
and Tu G: GPR30-mediated HMGB1 upregulation in CAFs induces
autophagy and tamoxifen resistance in ERα-positive breast cancer
cells. Aging. 13:16178–16197. 2021. View Article : Google Scholar
|
|
37
|
Wei Y, Tang X, Ren Y, Yang Y, Song F, Fu
J, Liu S, Yu M, Chen J, Wang S, et al: An RNA-RNA crosstalk network
involving HMGB1 and RICTOR facilitates hepatocellular carcinoma
tumorigenesis by promoting glutamine metabolism and impedes
immunotherapy by PD-L1+ exosomes activity. Signal Transduct Target
Ther. 6:4212021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chai W, Ye F, Zeng L, Li Y and Yang L:
HMGB1-mediated autophagy regulates sodium/iodide symporter protein
degradation in thyroid cancer cells. J Exp Clin Cancer Res.
38:3252019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao M, Zhang Y, Jiang Y, Wang K, Wang X,
Zhou D, Wang Y, Yu R and Zhou X: YAP promotes autophagy and
progression of gliomas via upregulating HMGB1. J Exp Clin Cancer
Res. 40:992021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hubert P, Roncarati P, Demoulin S, Pilard
C, Ancion M, Reynders C, Lerho T, Bruyere D, Lebeau A, Radermecker
C, et al: Extracellular HMGB1 blockade inhibits tumor growth
through profoundly remodeling immune microenvironment and enhances
checkpoint inhibitor-based immunotherapy. J Immunother Cancer.
9:e0019662021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zha C, Meng X, Li L, Mi S, Qian D, Li Z,
Wu P, Hu S, Zhao S, Cai J and Liu Y: Neutrophil extracellular traps
mediate the crosstalk between glioma progression and the tumor
microenvironment via the HMGB1/RAGE/IL-8 axis. Cancer Biol Med.
17:154–168. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chou YE, Yang PJ, Lin CY, Chen YY, Chiang
WL, Lin PX, Huang ZY, Huang M, Ho YC and Yang SF: The Impact of
HMGB1 Polymorphisms on Prostate Cancer Progression and
Clinicopathological Characteristics. Int J Environ Res Public
Health. 17:13322020. View Article : Google Scholar
|
|
43
|
Wang JB, Li P, Liu XL, Zheng QL, Ma YB,
Zhao YJ, Xie JW, Lin JX, Lu J, Chen QY, et al: An immune checkpoint
score system for prognostic evaluation and adjuvant chemotherapy
selection in gastric cancer. Nat Commun. 11:63522020. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kam NW, Wu KC, Dai W, Wang Y, Yan LYC,
Shakya R, Khanna R, Qin Y, Law S, Lo AWI, et al: Peritumoral B
cells drive proangiogenic responses in HMGB1-enriched esophageal
squamous cell carcinoma. Angiogenesis. 25:181–203. 2022. View Article : Google Scholar
|
|
45
|
Gong W, Zheng Y, Chao F, Li Y, Xu Z, Huang
G, Gao X, Li S and He F: The anti-inflammatory activity of HMGB1 A
box is enhanced when fused with C-terminal acidic tail. J Biomed
Biotechnol. 2010:9152342010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang S and Zhang Y: HMGB1 in inflammation
and cancer. J Hematol Oncol. 13:1162020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Huebener P, Gwak GY, Pradere JP, Quinzii
CM, Friedman R, Lin CS, Trent CM, Mederacke I, Zhao E, Dapito DH,
et al: High-mobility group box 1 is dispensable for autophagy,
mitochondrial quality control, and organ function in vivo. Cell
Metab. 19:539–547. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Rapoport BL, Steel HC, Theron AJ, Heyman
L, Smit T, Ramdas Y and Anderson R: High mobility group Box 1 in
human cancer. Cells. 9:16642020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kang R, Zhang Q, Zeh HJ III, Lotze MT and
Tang D: HMGB1 in cancer: Good, bad, or both? Clin Cancer Res.
19:4046–4057. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Amornsupak K, Thongchot S, Thinyakul C,
Box C, Hedayat S, Thuwajit P, Eccles SA and Thuwajit C: HMGB1
mediates invasion and PD-L1 expression through RAGE-PI3K/AKT
signaling pathway in MDA-MB-231 breast cancer cells. BMC Cancer.
22:5782022. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Jiang J, Wang GZ, Wang Y, Huang HZ, Li WT
and Qu XD: Hypoxia-induced HMGB1 expression of HCC promotes tumor
invasiveness and metastasis via regulating macrophage-derived IL-6.
Exp Cell Res. 367:81–88. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Hernandez C, Huebener P, Pradere JP,
Antoine DJ, Friedman RA and Schwabe RF: HMGB1 links chronic liver
injury to progenitor responses and hepatocarcinogenesis. J Clin
Invest. 128:2436–2451. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang H, Wang J, Li J, Zhou X, Yin L, Wang
Y, Gu Y, Niu X, Yang Y, Ji H and Zhang Q: HMGB1 is a key factor for
tamoxifen resistance and has the potential to predict the efficacy
of CDK4/6 inhibitors in breast cancer. Cancer Sci. 112:1603–1613.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Tan G, Huang C, Chen J and Zhi F: HMGB1
released from GSDME-mediated pyroptotic epithelial cells
participates in the tumorigenesis of colitis-associated colorectal
cancer through the ERK1/2 pathway. J Hematol Oncol. 13:1492020.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li Pomi F, Borgia F, Custurone P, Vaccaro
M, Pioggia G and Gangemi S: Role of HMGB1 in Cutaneous Melanoma:
State of the Art. Int J Mol Sci. 23:93272022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Gao Q, Wang S, Chen X, Cheng S, Zhang Z,
Li F, Huang L, Yang Y, Zhou B, Yue D, et al: Cancer-cell-secreted
CXCL11 promoted CD8+ T cells infiltration through
docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer.
7:422019. View Article : Google Scholar
|
|
57
|
Zhang X, Shi H, Yuan X, Jiang P, Qian H
and Xu W: Tumor-derived exosomes induce N2 polarization of
neutrophils to promote gastric cancer cell migration. Mol Cancer.
17:1462018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Ye F, Chai W, Xie M, Yang M, Yu Y, Cao L
and Yang L: HMGB1 regulates erastin-induced ferroptosis via
RAS-JNK/p38 signaling in HL-60/NRAS(Q61L) cells. Am J Cancer Res.
9:730–739. 2019.PubMed/NCBI
|
|
59
|
Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian
D, Lotze M, Tang D and Tsung A: Hypoxia induced HMGB1 and
mitochondrial DNA interactions mediate tumor growth in
hepatocellular carcinoma through Toll-like receptor 9. J Hepatol.
63:114–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Liang L, Fu J, Wang S, Cen H, Zhang L,
Mandukhail SR, Du L, Wu Q, Zhang P and Yu X: MiR-142-3p enhances
chemosensitivity of breast cancer cells and inhibits autophagy by
targeting HMGB1. Acta Pharm Sin B. 10:1036–1046. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chen Y, Cai L, Guo X, Li Z, Liao X, Zhang
X, Huang L and He J: HMGB1-activated fibroblasts promote breast
cancer cells metastasis via RAGE/aerobic glycolysis. Neoplasma.
68:71–78. 2021. View Article : Google Scholar
|
|
62
|
Lee HJ, Kim A, Song IH, Park IA, Yu JH,
Ahn JH and Gong G: Cytoplasmic expression of high mobility group B1
(HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in
breast cancer. Pathol Int. 66:202–209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yuan S, Liu Z, Xu Z, Liu J and Zhang J:
High mobility group box 1 (HMGB1): A pivotal regulator of
hematopoietic malignancies. J Hematol Oncol. 13:912020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yasinska IM, Gonçalves Silva I, Sakhnevych
SS, Ruegg L, Hussain R, Siligardi G, Fiedler W, Wellbrock J,
Bardelli M, Varani L, et al: High mobility group box 1 (HMGB1) acts
as an 'alarmin' to promote acute myeloid leukaemia progression.
Oncoimmunology. 7:e14381092018. View Article : Google Scholar
|
|
65
|
Liu L, Zhang J, Zhang X, Cheng P, Liu L,
Huang Q, Liu H, Ren S, Wei P, Wang C, et al: HMGB1: An important
regulator of myeloid differentiation and acute myeloid leukemia as
well as a promising therapeutic target. J Mol Med (Berl).
99:107–118. 2021. View Article : Google Scholar
|
|
66
|
Zhao M, Yang M, Yang L, Yu Y, Xie M, Zhu
S, Kang R, Tang D, Jiang Z, Yuan W, et al: HMGB1 regulates
autophagy through increasing transcriptional activities of JNK and
ERK in human myeloid leukemia cells. BMB Rep. 44:601–606. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Ding C, Yu H, Shi C, Shi T, Qin H and Cui
Y: MiR-let-7e inhibits invasion and magration and regulates HMGB1
expression in papillary thyroid carcinoma. Biomed Pharmacother.
110:528–536. 2019. View Article : Google Scholar
|
|
68
|
Wang CQ, Huang BF, Wang Y, Tang CH, Jin
HC, Shao F, Shao JK, Wang Q and Zeng Y: Subcellular localization of
HMGB1 in colorectal cancer impacts on tumor grade and survival
prognosis. Sci Rep. 10:185872020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Qian F, Xiao J, Gai L and Zhu J:
HMGB1-RAGE signaling facilitates Ras-dependent Yap1 expression to
drive colorectal cancer stemness and development. Mol Carcinog.
58:500–510. 2019. View Article : Google Scholar
|
|
70
|
Zhang JL, Zheng HF, Li K and Zhu YP:
miR-495-3p depresses cell proliferation and migration by
downregulating HMGB1 in colorectal cancer. World J Surg Oncol.
20:1012022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Wu X, Wang W, Chen Y, Liu X, Wang J, Qin
X, Yuan D, Yu T, Chen G, Mi Y, et al: High mobility group box
Protein 1 serves as a potential prognostic marker of lung cancer
and promotes its invasion and metastasis by matrix
Metalloproteinase-2 in a nuclear Factor-κB-dependent manner. Biomed
Res Int. 2018:34537062018.
|
|
72
|
Zhou Y, Liu SX, Zhou YN, Wang J and Ji R:
Research on the relationship between RAGE and its ligand HMGB1, and
prognosis and pathogenesis of gastric cancer with diabetes
mellitus. Eur Rev Med Pharmacol Sci. 25:1339–1350. 2021.PubMed/NCBI
|
|
73
|
van Beijnum JR, Nowak-Sliwinska P, van den
Boezem E, Hautvast P, Buurman WA and Griffioen AW: Tumor
angiogenesis is enforced by autocrine regulation of high-mobility
group box 1. Oncogene. 32:363–374. 2013. View Article : Google Scholar
|
|
74
|
van Beijnum JR, Buurman WA and Griffioen
AW: Convergence and amplification of toll-like receptor (TLR) and
receptor for advanced glycation end products (RAGE) signaling
pathways via high mobility group B1 (HMGB1). Angiogenesis.
11:91–99. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Zhu L, Li X, Chen Y, Fang J and Ge Z:
High-mobility group box 1: A novel inducer of the
epithelial-mesenchymal transition in colorectal carcinoma. Cancer
Lett. 357:527–534. 2015. View Article : Google Scholar
|
|
76
|
Kuniyasu H, Chihara Y and Kondo H:
Differential effects between amphoterin and advanced glycation end
products on colon cancer cells. Int J Cancer. 104:722–727. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Sharma S, Evans A and Hemers E:
Mesenchymal-epithelial signalling in tumour microenvironment: Role
of high-mobility group Box 1. Cell Tissue Res. 365:357–366. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Gialeli C, Theocharis AD and Karamanos NK:
Roles of matrix metalloproteinases in cancer progression and their
pharmacological targeting. FEBS J. 278:16–27. 2011. View Article : Google Scholar
|
|
79
|
Liu PL, Liu WL, Chang JM, Chen YH, Liu YP,
Kuo HF, Hsieh CC, Ding YS, Chen WW and Chong IW: MicroRNA-200c
inhibits epithelial-mesenchymal transition, invasion, and migration
of lung cancer by targeting HMGB1. PLoS One. 12:e01808442017.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Yao S, Zhao T and Jin H: Expression of
MicroRNA-325-3p and its potential functions by targeting HMGB1 in
non-small cell lung cancer. Biomed Pharmacother. 70:72–79. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zhou J, Chen X, Gilvary DL, Tejera MM,
Eksioglu EA, Wei S and Djeu JY: HMGB1 induction of clusterin
creates a chemoresistant niche in human prostate tumor cells. Sci
Rep. 5:150852015. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Liao M, Qin R, Huang W, Zhu HP, Peng F,
Han B and Liu B: Targeting regulated cell death (RCD) with
small-molecule compounds in triple-negative breast cancer: A
revisited perspective from molecular mechanisms to targeted
therapies. J Hematol Oncol. 15:442022. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bahar E, Han SY, Kim JY and Yoon H:
Chemotherapy resistance: Role of mitochondrial and autophagic
components. Cancers (Basel). 14:14622022. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Ge R, Liu L, Dai W, Zhang W, Yang Y, Wang
H, Shi Q, Guo S, Yi X, Wang G, et al: Xeroderma pigmentosum Group A
promotes autophagy to facilitate cisplatin resistance in melanoma
cells through the activation of PARP1. J Invest Dermatol.
136:1219–1228. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Ferreira PMP, Sousa RWR, Ferreira JRO,
Militão GCG and Bezerra DP: Chloroquine and hydroxychloroquine in
antitumor therapies based on autophagy-related mechanisms.
Pharmacol Res. 168:1055822021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Kim JS, Lee JM, Chwae YJ, Kim YH, Lee JH,
Kim K, Lee TH, Kim SJ and Park JH: Cisplatin-induced apoptosis in
Hep3B cells: Mitochondria-dependent and -independent pathways.
Biochem Pharmacol. 67:1459–1468. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Çoku J, Booth DM, Skoda J, Pedrotty MC,
Vogel J, Liu K, Vu A, Carpenter EL, Ye JC, Chen MA, et al: Reduced
ER-mitochondria connectivity promotes neuroblastoma multidrug
resistance. EMBO J. 41:e1082722022. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yang M, Liu L, Xie M, Sun X, Yu Y, Kang R,
Yang L, Zhu S, Cao L and Tang D: Poly-ADP-ribosylation of HMGB1
regulates TNFSF10/TRAIL resistance through autophagy. Autophagy.
11:214–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Pal Singh M, Pal Khaket T, Bajpai VK,
Alfarraj S, Kim SG, Chen L, Huh YS, Han YK and Kang SC: Morin
Hydrate Sensitizes Hepatoma Cells and Xenograft Tumor towards
Cisplatin by Downregulating PARP-1-HMGB1 Mediated Autophagy. Int J
Mol Sci. 21:82532020. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Tang D, Loze MT, Zeh HJ and Kang R: The
redox protein HMGB1 regulates cell death and survival in cancer
treatment. Autophagy. 6:1181–1183. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Tang D, Kang R, Livesey KM, Cheh CW,
Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ III
and Lotze MT: Endogenous HMGB1 regulates autophagy. J Cell Biol.
190:881–892. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Tang D, Kang R, Livesey KM, Cheh CW,
Farkas A, Loughran P, Hoppe G, Bianchi ME, Tracey KJ, Zeh HJ III
and Lotze MT: HMGB1 release and redox regulates autophagy and
apoptosis in cancer cells. Oncogene. 29:5299–5310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Singh MP, Cho HJ, Kim JT, Baek KE, Lee HG
and Kang SC: Morin hydrate reverses cisplatin resistance by
impairing PARP1/HMGB1-dependent autophagy in hepatocellular
carcinoma. Cancers (Basel). 11:9862019. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Shi Q, Wang Y, Dong W, Song E and Song Y:
Polychlorinated biphenyl quinone-induced signaling transition from
autophagy to apoptosis is regulated by HMGB1 and p53 in human
hepatoma HepG2 cells. Toxicol Lett. 306:25–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Shi Y, Gong W, Lu L, Wang Y and Ren J:
Upregulation of miR-129-5p increases the sensitivity to Taxol
through inhibiting HMGB1-mediated cell autophagy in breast cancer
MCF-7 cells. Braz J Med Biol Res. 52:e86572019. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Zhang Y, Chu X and Wei Q: MiR-451 promotes
cell apoptosis and inhibits autophagy in pediatric acute myeloid
leukemia by targeting HMGB1. J Environ Pathol Toxicol Oncol.
40:45–53. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Run L, Wang L, Nong X, Li N, Huang X and
Xiao Y: Involvement of HMGB1 in vemurafenib resistance in thyroid
cancer cells harboring BRAF (V600E) mutation by regulating
excessive autophagy. Endocrine. 71:418–426. 2021. View Article : Google Scholar
|
|
98
|
Mou K, Liu W, Han D and Li P: HMGB1/RAGE
axis promotes autophagy and protects keratinocytes from ultraviolet
radiation-induced cell death. J Dermatol Sci. 85:162–169. 2017.
View Article : Google Scholar
|
|
99
|
Li H, Li J, Zhang G, Da Q, Chen L, Yu S,
Zhou Q, Weng Z, Xin Z, Shi L, et al: HMGB1-induced p62
overexpression promotes snail-mediated epithelial-mesenchymal
transition in glioblastoma cells via the degradation of GSK-3β.
Theranostics. 9:1909–1922. 2019. View Article : Google Scholar :
|
|
100
|
Liu W, Zhang Z, Zhang Y, Chen X, Guo S,
Lei Y, Xu Y, Ji C, Bi Z and Wang K: HMGB1-mediated autophagy
modulates sensitivity of colorectal cancer cells to oxaliplatin via
MEK/ERK signaling pathway. Cancer Biol Ther. 16:511–517. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Chen SY, Hsu YH, Wang SY, Chen YY, Hong CJ
and Yen GC: Lucidone inhibits autophagy and MDR1 via
HMGB1/RAGE/PI3K/Akt signaling pathway in pancreatic cancer cells.
Phytother Res. 36:1664–1677. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Luo P, Xu Z, Li G, Yan H, Zhu Y, Zhu H, Ma
S, Yang B and He Q: HMGB1 represses the anti-cancer activity of
sunitinib by governing TP53 autophagic degradation via its
nucleus-to-cytoplasm transport. Autophagy. 14:2155–2170. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Cao JY and Dixon SJ: Mechanisms of
ferroptosis. Cell Mol Life Sci. 73:2195–2209. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Liang C, Zhang X, Yang M and Dong X:
Recent progress in ferroptosis inducers for cancer therapy. Adv
Mater. 31:e19041972019. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Yan HF, Zou T, Tuo QZ, Xu S, Li H, Belaidi
AA and Lei P: Ferroptosis: Mechanisms and links with diseases.
Signal Transduct Target Ther. 6:492021. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Hassannia B, Vandenabeele P and Vanden
Berghe T: Targeting ferroptosis to Iron out cancer. Cancer Cell.
35:830–849. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Stockwell BR: Ferroptosis turns 10:
Emerging mechanisms, physiological functions, and therapeutic
applications. Cell. 185:2401–2421. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Sosa V, Moliné T, Somoza R, Paciucci R,
Kondoh H and ME LL: Oxidative stress and cancer: An overview.
Ageing Res Rev. 12:376–390. 2013. View Article : Google Scholar
|
|
110
|
Wang D, Tang L, Zhang Y, Ge G, Jiang X, Mo
Y, Wu P, Deng X, Li L, Zuo S, et al: Regulatory pathways and drugs
associated with ferroptosis in tumors. Cell Death Dis. 13:5442022.
View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Chen R, Kang R and Tang D: The mechanism
of HMGB1 secretion and release. Exp Mol Med. 54:91–102. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wen Q, Liu J, Kang R, Zhou B and Tang D:
The release and activity of HMGB1 in ferroptosis. Biochem Biophys
Res Commun. 510:278–283. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wiernicki B, Maschalidi S, Pinney J,
Adjemian S, Vanden Berghe T, Ravichandran KS and Vandenabeele P:
Cancer cells dying from ferroptosis impede dendritic cell-mediated
anti-tumor immunity. Nat Commun. 13:36762022. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Efimova I, Catanzaro E, Van der Meeren L,
Turubanova VD, Hammad H, Mishchenko TA, Vedunova MV, Fimognari C,
Bachert C, Coppieters F, et al: Vaccination with early ferroptotic
cancer cells induces efficient antitumor immunity. J Immunother
Cancer. 8:e0013692020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Vats K, Kruglov O, Mizes A, Samovich SN,
Amoscato AA, Tyurin VA, Tyurina YY, Kagan VE and Bunimovich YL:
Keratinocyte death by ferroptosis initiates skin inflammation after
UVB exposure. Redox Biol. 47:1021432021. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Zhang H, Wang Z, Liu Z, Du K and Lu X:
Protective effects of dexazoxane on rat ferroptosis in
doxorubicin-induced cardiomyopathy through regulating HMGB1. Front
Cardiovasc Med. 8:6854342021. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Friedmann Angeli JP, Krysko DV and Conrad
M: Ferroptosis at the crossroads of cancer-acquired drug resistance
and immune evasion. Nat Rev Cancer. 19:405–414. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Chaudhary N, Choudhary BS, Shah SG,
Khapare N, Dwivedi N, Gaikwad A, Joshi N, Raichanna J, Basu S,
Gurjar M, et al: Lipocalin 2 expression promotes tumor progression
and therapy resistance by inhibiting ferroptosis in colorectal
cancer. Int J Cancer. 149:1495–1511. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
You JH, Lee J and Roh JL: PGRMC1-dependent
lipophagy promotes ferroptosis in paclitaxel-tolerant persister
cancer cells. J Exp Clin Cancer Res. 40:3502021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Lee J, You JH, Shin D and Roh JL:
Inhibition of Glutaredoxin 5 predisposes Cisplatin-resistant head
and neck cancer cells to ferroptosis. Theranostics. 10:7775–7786.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wu D, Wang S, Yu G and Chen X: Cell death
mediated by the pyroptosis pathway with the aid of nanotechnology:
Prospects for cancer therapy. Angew Chem Int Ed Engl. 60:8018–8034.
2021. View Article : Google Scholar
|
|
122
|
Qi S, Wang Q, Zhang J, Liu Q and Li C:
Pyroptosis and its role in the modulation of cancer progression and
antitumor immunity. Int J Mol Sci. 23:104942022. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Hage C, Hoves S, Strauss L, Bissinger S,
Prinz Y, Pöschinger T, Kiessling F and Ries CH: Sorafenib induces
pyroptosis in macrophages and triggers natural killer cell-mediated
cytotoxicity against hepatocellular carcinoma. Hepatology.
70:1280–1297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Wu LS, Liu Y, Wang XW, Xu B, Lin YL, Song
Y, Dong Y, Liu JL, Wang XJ, Liu S, et al: LPS enhances the
chemosensitivity of oxaliplatin in HT29 cells via GSDMD-mediated
pyroptosis. Cancer Manag Res. 12:10397–10409. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Tang Z, Ji L, Han M, Xie J, Zhong F, Zhang
X, Su Q, Yang Z, Liu Z, Gao H and Jiang G: Pyroptosis is involved
in the inhibitory effect of FL118 on growth and metastasis in
colorectal cancer. Life Sci. 257:1180652020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yu J, Li S, Qi J, Chen Z, Wu Y, Guo J,
Wang K, Sun X and Zheng J: Cleavage of GSDME by caspase-3
determines lobaplatin-induced pyroptosis in colon cancer cells.
Cell Death Dis. 10:1932019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Wang F, Liu W, Ning J, Wang J, Lang Y, Jin
X, Zhu K, Wang X, Li X, Yang F, et al: Simvastatin suppresses
proliferation and migration in non-small cell lung cancer via
pyroptosis. Int J Biol Sci. 14:406–417. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wu L, Lu H, Pan Y, Liu C, Wang J, Chen B
and Wang Y: The role of pyroptosis and its crosstalk with immune
therapy in breast cancer. Front Immunol. 13:9739352022. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Yu P, Zhang X, Liu N, Tang L, Peng C and
Chen X: Pyroptosis: Mechanisms and diseases. Signal Transduct
Target Ther. 6:1282021. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Xia X, Wang X, Cheng Z, Qin W, Lei L,
Jiang J and Hu J: The role of pyroptosis in cancer: Pro-cancer or
pro-'host'? Cell Death Dis. 10:6502019. View Article : Google Scholar
|
|
131
|
Volchuk A, Ye A, Chi L, Steinberg BE and
Goldenberg NM: Indirect regulation of HMGB1 release by gasdermin D.
Nat Commun. 11:45612020. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Deng M, Tang Y, Li W, Wang X, Zhang R,
Zhang X, Zhao X, Liu J, Tang C, Liu Z, et al: The endotoxin
delivery protein HMGB1 mediates Caspase-11-dependent lethality in
sepsis. Immunity. 49:740–753.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Hou W, Wei X, Liang J, Fang P, Ma C, Zhang
Q and Gao Y: HMGB1-induced hepatocyte pyroptosis expanding
inflammatory responses contributes to the pathogenesis of
Acute-on-chronic liver failure (ACLF). J Inflamm Res. 14:7295–7313.
2021. View Article : Google Scholar
|
|
134
|
Peng Z, Wang P, Song W, Yao Q, Li Y, Liu
L, Li Y and Zhou S: GSDME enhances Cisplatin sensitivity to regress
non-small cell lung carcinoma by mediating pyroptosis to trigger
antitumor immunocyte infiltration. Signal Transduct Target Ther.
5:1592020. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Shi F, Zhang L, Liu X and Wang Y:
Knock-down of microRNA miR-556-5p increases cisplatin-sensitivity
in non-small cell lung cancer (NSCLC) via activating NLR family
pyrin domain containing 3 (NLRP3)-mediated pyroptotic cell death.
Bioengineered. 12:6332–6342. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Erkes DA, Cai W, Sanchez IM, Purwin TJ,
Rogers C, Field CO, Berger AC, Hartsough EJ, Rodeck U, Alnemri ES
and Aplin AE: Mutant BRAF and MEK inhibitors regulate the tumor
immune microenvironment via pyroptosis. Cancer Discov. 10:254–269.
2020. View Article : Google Scholar :
|
|
137
|
Chen B, Dragomir MP, Yang C, Li Q, Horst D
and Calin GA: Targeting non-coding RNAs to overcome cancer therapy
resistance. Signal Transduct Target Ther. 7:1212022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Barth DA, Drula R, Ott L, Fabris L, Slaby
O, Calin GA and Pichler M: Circulating Non-coding RNAs in renal
cell carcinoma-pathogenesis and potential implications as clinical
biomarkers. Front Cell Dev Biol. 8:8282020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zeuschner P, Linxweiler J and Junker K:
Non-coding RNAs as biomarkers in liquid biopsies with a special
emphasis on extracellular vesicles in urological malignancies.
Expert Rev Mol Diagn. 20:151–167. 2020. View Article : Google Scholar
|
|
140
|
Barth DA, Slaby O, Klec C, Juracek J,
Drula R, Calin GA and Pichler M: Current concepts of Non-coding
RNAs in the pathogenesis of non-clear cell renal cell carcinoma.
Cancers (Basel). 11:15802019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Grimson A, Farh KK, Johnston WK,
Garrett-Engele P, Lim LP and Bartel DP: MicroRNA targeting
specificity in mammals: Determinants beyond seed pairing. Mol Cell.
27:91–105. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi
S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers,
therapies, and resistance in Cancer. Int J Biol Sci. 16:2628–2647.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Taheri M, Shirvani-Farsani Z,
Ghafouri-Fard S and Omrani MD: Expression profile of microRNAs in
bladder cancer and their application as biomarkers. Biomed
Pharmacother. 131:1107032020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Deng H, Lv L, Li Y, Zhang C, Meng F, Pu Y,
Xiao J, Qian L, Zhao W, Liu Q, et al: miR-193a-3p regulates the
multi-drug resistance of bladder cancer by targeting the LOXL4 gene
and the oxidative stress pathway. Mol Cancer. 13:2342014.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Díaz-Martínez M, Benito-Jardón L, Alonso
L, Koetz-Ploch L, Hernando E and Teixidó J: miR-204-5p and
miR-211-5p Contribute to BRAF inhibitor resistance in melanoma.
Cancer Res. 78:1017–1030. 2018. View Article : Google Scholar :
|
|
146
|
Sur S and Ray RB: Emerging role of lncRNA
ELDR in development and cancer. FEBS J. 289:3011–3023. 2022.
View Article : Google Scholar
|
|
147
|
Zhu L, Zhu Y, Han S, Chen M, Song P, Dai
D, Xu W, Jiang T, Feng L, Shin VY, et al: Impaired autophagic
degradation of lncRNA ARHGAP5-AS1 promotes chemoresistance in
gastric cancer. Cell Death Dis. 10:3832019. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Luo Y, Zheng S, Wu Q, Wu J, Zhou R, Wang
C, Wu Z, Rong X, Huang N, Sun L, et al: Long noncoding RNA (lncRNA)
EIF3J-DT induces chemoresistance of gastric cancer via autophagy
activation. Autophagy. 17:4083–4101. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Lu J, Xu Y, Xie W, Tang Y, Zhang H, Wang
B, Mao J, Rui T, Jiang P and Zhang W: Long noncoding RNA DLGAP1-AS2
facilitates Wnt1 transcription through physically interacting with
Six3 and drives the malignancy of gastric cancer. Cell Death
Discov. 7:2552021. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Ren C, Han H, Pan J, Chang Q, Wang W, Guo
X and Bian J: DLGAP1-AS2 promotes human colorectal cancer
progression through trans-activation of Myc. Mamm Genome.
33:672–683. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Li Q, Sun H, Luo D, Gan L, Mo S, Dai W,
Liang L, Yang Y, Xu M, Li J, et al: Lnc-RP11-536 K7.3/SOX2/HIF-1α
signaling axis regulates oxaliplatin resistance in patient-derived
colorectal cancer organoids. J Exp Clin Cancer Res. 40:3482021.
View Article : Google Scholar
|
|
152
|
Chioccarelli T, Falco G, Cappetta D, De
Angelis A, Roberto L, Addeo M, Ragusa M, Barbagallo D, Berrino L,
Purrello M, et al: FUS driven circCNOT6L biogenesis in mouse and
human spermatozoa supports zygote development. Cell Mol Life Sci.
79:502021. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Singh V, Uddin MH, Zonder JA, Azmi AS and
Balasubramanian SK: Circular RNAs in acute myeloid leukemia. Mol
Cancer. 20:1492021. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Chen DL, Sheng H, Zhang DS, Jin Y, Zhao
BT, Chen N, Song K and Xu RH: The circular RNA circDLG1 promotes
gastric cancer progression and anti-PD-1 resistance through the
regulation of CXCL12 by sponging miR-141-3p. Mol Cancer.
20:1662021. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Li P, Song R, Yin F, Liu M, Liu H, Ma S,
Jia X, Lu X, Zhong Y, Yu L, et al: circMRPS35 promotes malignant
progression and cisplatin resistance in hepatocellular carcinoma.
Mol Ther. 30:431–447. 2022. View Article : Google Scholar :
|
|
156
|
Zhang Y, Liu Y and Xu X: Upregulation of
miR-142-3p improves drug sensitivity of acute myelogenous leukemia
through reducing P-glycoprotein and repressing autophagy by
targeting HMGB1. Transl Oncol. 10:410–418. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
LeClair K, Bell KJL, Furuya-Kanamori L,
Doi SA, Francis DO and Davies L: Evaluation of gender inequity in
thyroid cancer diagnosis: Differences by Sex in US thyroid cancer
incidence compared with a meta-analysis of subclinical thyroid
cancer rates at autopsy. JAMA Internal Med. 181:1351–1358. 2021.
View Article : Google Scholar
|
|
158
|
Lei T, Huang J, Xie F, Gu J, Cheng Z and
Wang Z: HMGB1-mediated autophagy promotes gefitinib resistance in
human non-small cell lung cancer. Acta Biochim Biophys Sin
(Shanghai). 54:fpage–lpage. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Kishi S, Fujiwara-Tani R, Honoki K, Sasaki
R, Mori S, Ohmori H, Sasaki T, Miyagawa Y, Kawahara I, Kido A, et
al: Oxidized high mobility group B-1 enhances metastability of
colorectal cancer via modification of mesenchymal stem/stromal
cells. Cancer Sci. 113:2904–2915. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Ren Y, Cao L, Wang L, Zheng S, Zhang Q,
Guo X, Li X, Chen M, Wu X, Furlong F, et al: Autophagic secretion
of HMGB1 from cancer-associated fibroblasts promotes metastatic
potential of non-small cell lung cancer cells via NFκB signaling.
Cell Death Dis. 12:8582021. View Article : Google Scholar
|
|
161
|
Ning J, Yang R, Wang H and Cui L: HMGB1
enhances chemotherapy resistance in multiple myeloma cells by
activating the nuclear factor-κB pathway. Exp Ther Med. 22:7052021.
View Article : Google Scholar
|
|
162
|
Zhou P, Zheng ZH, Wan T, Wu J, Liao CW and
Sun XJ: Vitexin inhibits gastric cancer growth and metastasis
through HMGB1-mediated inactivation of the PI3K/AKT/mTOR/HIF-1α
signaling pathway. J Gastric Cancer. 21:439–456. 2021. View Article : Google Scholar
|
|
163
|
Pu Z, Duda DG, Zhu Y, Pei S, Wang X, Huang
Y, Yi P, Huang Z, Peng F, Hu X and Fan X: VCP interaction with
HMGB1 promotes hepatocellular carcinoma progression by activating
the PI3K/AKT/mTOR pathway. J Transl Med. 20:2122022. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Zhang X, Zou N, Deng W, Song C, Yan K,
Shen W and Zhu S: HMGB1 induces radioresistance through
PI3K/AKT/ATM pathway in esophageal squamous cell carcinoma. Mol
Biol Rep. 49:11933–11945. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Xu HZ, Li TF, Wang C, Ma Y, Liu Y, Zheng
MY, Liu ZJ, Chen JB, Li K, Sun SK, et al: Synergy of
nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively
turns tumor-associated macrophages against tumor cells. J
Nanobiotechnol. 19:2682021. View Article : Google Scholar
|
|
166
|
Yang L, Yu Y, Kang R, Yang M, Xie M, Wang
Z, Tang D, Zhao M, Liu L, Zhang H and Cao L: Up-regulated autophagy
by endogenous high mobility group box-1 promotes chemoresistance in
leukemia cells. Leuk Lymphoma. 53:315–322. 2012. View Article : Google Scholar
|
|
167
|
Liu N, Wu Y, Wen X, Li P, Lu F and Shang
H: Chronic stress promotes acute myeloid leukemia progression
through HMGB1/NLRP3/IL-1β signaling pathway. J Mol Med (Berl).
99:403–414. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Wei L, Wang Z, Jing N, Lu Y, Yang J, Xiao
H, Guo H, Sun S, Li M, Zhao D, et al: Frontier progress of the
combination of modern medicine and traditional Chinese medicine in
the treatment of hepatocellular carcinoma. Chin Med. 17:902022.
View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Wei J, Liu Z, He J, Liu Q, Lu Y, He S,
Yuan B, Zhang J and Ding Y: Traditional Chinese medicine reverses
cancer multidrug resistance and its mechanism. Clin Transl Oncol.
24:471–482. 2022. View Article : Google Scholar
|
|
170
|
Xi S, Peng Y, Minuk GY, Shi M, Fu B, Yang
J, Li Q, Gong Y, Yue L, Li L, et al: The combination effects of
Shen-Ling-Bai-Zhu on promoting apoptosis of transplanted H22
hepatocellular carcinoma in mice receiving chemotherapy. J
Ethnopharmacol. 190:1–12. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Wang H, Li Y, Lu J, Qiu M, Cheng D, Zhang
X and Yuan W: Shengbai decoction enhances the anti-tumor efficacy
of cyclophosphamide on hepatoma 22-bearing mice. Biomed
Pharmacother. 140:1117752021. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Xi S, Zhai X, Wang Y, Gong Y, Fu B, Gao C,
Guo X, Li Y, Wang Z, Huang S, et al: The Ciji-Hua'ai-Baosheng II
formula attenuates chemotherapy-induced anorexia in mice with
H22 hepatocellular carcinoma. Front Pharmacol.
12:7158242021. View Article : Google Scholar
|
|
173
|
Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH,
Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, et al: Artesunate
synergizes with sorafenib to induce ferroptosis in hepatocellular
carcinoma. Acta Pharmacol Sin. 42:301–310. 2021. View Article : Google Scholar :
|
|
174
|
Ming JX, Wang ZC, Huang Y, Ohishi H, Wu
RJ, Shao Y, Wang H, Qin MY, Wu ZL, Li YY, et al: Fucoxanthin
extracted from Laminaria Japonica inhibits metastasis and enhances
the sensitivity of lung cancer to Gefitinib. J Ethnopharmacol.
265:1133022021. View Article : Google Scholar
|
|
175
|
Li Y, Liu T, Li Y, Han D, Hong J, Yang N,
He J, Peng R, Mi X, Kuang C, et al: Baicalin ameliorates cognitive
impairment and protects microglia from LPS-induced
neuroinflammation via the SIRT1/HMGB1 pathway. Oxid Med Cell
Longev. 2020:47513492020. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Yan G, Chen L, Wang H, Wu S, Li S and Wang
X: Baicalin inhibits LPS-induced inflammation in RAW264.7 cells
through miR-181b/HMGB1/TRL4/NF-κB pathway. Am J Transl Res.
13:10127–10141. 2021.
|
|
177
|
Chen P, Huang HP, Wang Y, Jin J, Long WG,
Chen K, Zhao XH, Chen CG and Li J: Curcumin overcome primary
gefitinib resistance in non-small-cell lung cancer cells through
inducing autophagy-related cell death. J Exp Clin Cancer Res.
38:2542019. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Wang Z, Chen W, Li Y, Zhang S, Lou H, Lu X
and Fan X: Reduning injection and its effective constituent
luteoloside protect against sepsis partly via inhibition of
HMGB1/TLR4/NF-κB/MAPKs signaling pathways. J Ethnopharmacol.
270:1137832021. View Article : Google Scholar
|
|
179
|
Wei X, Zhang B, Wei F, Ding M, Luo Z, Han
X and Tan X: Gegen Qinlian pills alleviate carrageenan-induced
thrombosis in mice model by regulating the HMGB1/NF-κB/NLRP3
signaling. Phytomedicine. 100:1540832022. View Article : Google Scholar
|
|
180
|
Roy M, Liang L, Xiao X, Peng Y, Luo Y,
Zhou W, Zhang J, Qiu L, Zhang S, Liu F, et al: Lycorine
downregulates HMGB1 to inhibit autophagy and enhances bortezomib
activity in multiple myeloma. Theranostics. 6:2209–2224. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Yu AM, Jian C, Yu AH and Tu MJ: RNA
therapy: Are we using the right molecules? Pharmacol Ther.
196:91–104. 2019. View Article : Google Scholar :
|
|
182
|
Kristensen LS, Andersen MS, Stagsted LVW,
Ebbesen KK, Hansen TB and Kjems J: The biogenesis, biology and
characterization of circular RNAs. Nat Rev Genet. 20:675–691. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Ngamcherdtrakul W and Yantasee W: siRNA
therapeutics for breast cancer: Recent efforts in targeting
metastasis, drug resistance, and immune evasion. Transl Res.
214:105–120. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Sharma P, Yadav P, Sundaram S, Venkatraman
G, Bera AK and Karunagaran D: HMGB3 inhibition by miR-142-3p/sh-RNA
modulates autophagy and induces apoptosis via ROS accumulation and
mitochondrial dysfunction and reduces the tumorigenic potential of
human breast cancer cells. Life Sci. 304:1207272022. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Sharma P, Yadav P, Jain RP, Bera AK and
Karunagaran D: miR-142-3p simultaneously targets HMGA1, HMGA2,
HMGB1, and HMGB3 and inhibits tumorigenic properties and in-vivo
metastatic potential of human cervical cancer cells. Life Sci.
291:1202682022. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Mukherjee A and Vasquez KM: Targeting
chromosomal architectural HMGB proteins could be the next frontier
in cancer therapy. Cancer Res. 80:2075–2082. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Wu T, Zhang W, Yang G, Li H, Chen Q, Song
R and Zhao L: HMGB1 overexpression as a prognostic factor for
survival in cancer: A meta-analysis and systematic review.
Oncotarget. 7:50417–50427. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Xie J, Yang Y, Gao Y and He J:
Cuproptosis: Mechanisms and links with cancers. Mol Cancer.
22:462023. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Liu J, Liu Y, Wang Y, Kang R and Tang D:
HMGB1 is a mediator of cuproptosis-related sterile inflammation.
Front Cell Dev Biol. 10:9963072022. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Hassannia B, Wiernicki B, Ingold I, Qu F,
Van Herck S, Tyurina YY, Bayır H, Abhari BA, Angeli JPF, Choi SM,
et al: Nano-targeted induction of dual ferroptotic mechanisms
eradicates high-risk neuroblastoma. J Clin Invest. 128:3341–3355.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Kim KS, Choi B, Choi H, Ko MJ and Kim DH
and Kim DH: Enhanced natural killer cell anti-tumor activity with
nanoparticles mediated ferroptosis and potential therapeutic
application in prostate cancer. J Nanobiotechnol. 20:4282022.
View Article : Google Scholar
|
|
192
|
Zheng X, Zhao Y, Jia Y, Shao D, Zhang F,
Sun M, Dawulieti J, Hu H, Cui L, Pan Y, et al: Biomimetic
co-assembled nanodrug of doxorubicin and berberine suppresses
chemotherapy-exacerbated breast cancer metastasis. Biomaterials.
271:1207162021. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Meng X, Lou QY, Yang WY, Wang YR, Chen R,
Wang L, Xu T and Zhang L: The role of non-coding RNAs in drug
resistance of oral squamous cell carcinoma and therapeutic
potential. Cancer Commun (Lond). 41:981–1006. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Jiang T, Qiao Y, Ruan W, Zhang D, Yang Q,
Wang G, Chen Q, Zhu F, Yin J, Zou Y, et al: Cation-free siRNA
micelles as effective drug delivery platform and potent RNAi
nanomedicines for glioblastoma therapy. Adv Mater. 33:e21047792021.
View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Fu S, Li G, Zang W, Zhou X, Shi K and Zhai
Y: Pure drug nano-assemblies: A facile carrier-free nanoplatform
for efficient cancer therapy. Acta Pharm Sin B. 12:92–106. 2022.
View Article : Google Scholar : PubMed/NCBI
|
